3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Lung Neoplasms
1
Lung Diseases
1
Interventions
Carboplatin
6
Pemetrexed
4
pembrolizumab
3
Cisplatin
3
Paclitaxel
2
Gemcitabine
2
Docetaxel
2
zipalertinib
1
zimberelimab
1
sacituzumab govitecan
1
pralsetinib
1
patritumab
1
camrelizumab
1
alectinib
1
Vinorelbine
1
Thrombin
1
Talc
1
TachoSil
1
TNFSF10 protein, human
1
Surveys and Questionnaires
1
Nivolumab
1
Injections
1
Fibrinogen
1
Erlotinib Hydrochloride
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lung Diseases
×
zipalertinib
×
Clear all
NCT05973773
2026-05-28
REZILIENT3
Taiho Oncology, Inc.
Phase 3
Active not recruiting
285 enrolled